- Home
- TNGX vs NEXN Comparison
TNGX vs NEXN Comparison
Compare TNGX & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- NEXN
- Stock Information
- Founded
- TNGX 2014
- NEXN 2007
- Country
- TNGX United States
- NEXN Israel
- Employees
- TNGX N/A
- NEXN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- NEXN Computer Software: Programming Data Processing
- Sector
- TNGX Health Care
- NEXN Technology
- Exchange
- TNGX Nasdaq
- NEXN Nasdaq
- Market Cap
- TNGX 723.2M
- NEXN 636.1M
- IPO Year
- TNGX N/A
- NEXN 2021
- Fundamental
- Price
- TNGX $8.76
- NEXN $8.64
- Analyst Decision
- TNGX Strong Buy
- NEXN Strong Buy
- Analyst Count
- TNGX 6
- NEXN 9
- Target Price
- TNGX $10.00
- NEXN $14.00
- AVG Volume (30 Days)
- TNGX 2.1M
- NEXN 516.1K
- Earning Date
- TNGX 11-06-2025
- NEXN 11-14-2025
- Dividend Yield
- TNGX N/A
- NEXN N/A
- EPS Growth
- TNGX N/A
- NEXN N/A
- EPS
- TNGX N/A
- NEXN 0.75
- Revenue
- TNGX $24,296,000.00
- NEXN $371,746,000.00
- Revenue This Year
- TNGX $20.42
- NEXN $5.43
- Revenue Next Year
- TNGX N/A
- NEXN N/A
- P/E Ratio
- TNGX N/A
- NEXN $11.49
- Revenue Growth
- TNGX N/A
- NEXN 9.65
- 52 Week Low
- TNGX $1.03
- NEXN $6.93
- 52 Week High
- TNGX $9.70
- NEXN $12.60
- Technical
- Relative Strength Index (RSI)
- TNGX 58.17
- NEXN 43.69
- Support Level
- TNGX $8.85
- NEXN $8.55
- Resistance Level
- TNGX $9.31
- NEXN $8.96
- Average True Range (ATR)
- TNGX 0.56
- NEXN 0.40
- MACD
- TNGX 0.08
- NEXN 0.03
- Stochastic Oscillator
- TNGX 67.60
- NEXN 38.62
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.